Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsCash from RestructuringChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Change in Cash (2019 - 2025)

Quarterly Change in Cash fell 136.73% to -$6.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$24.7 million through Dec 2025, down 231.12% year-over-year, with the annual reading at -$24.7 million for FY2025, 231.12% down from the prior year.

Lyra Therapeutics' Change in Cash history spans 7 years, with the latest figure at -$6.2 million for Q4 2025.

  • Change in Cash came in at -$6.2 million for Q4 2025, up from -$7.7 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $88.0 million in Q2 2022 to a low of -$77.0 million in Q4 2022.
  • The 5-year median for Change in Cash is -$7.9 million (2024), against an average of -$2.9 million.
  • The largest YoY upside for Change in Cash was 2892.28% in 2022 against a maximum downside of 522.04% in 2022.
  • Lyra Therapeutics' Change in Cash stood at -$12.4 million in 2021, then plummeted by 522.04% to -$77.0 million in 2022, then surged by 96.76% to -$2.5 million in 2023, then soared by 771.93% to $16.8 million in 2024, then crashed by 136.73% to -$6.2 million in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Change in Cash are -$6.2 million (Q4 2025), -$7.7 million (Q3 2025), and -$2.0 million (Q2 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Cash (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - 2.44 Mn
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn 623.00 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -2.44 Mn
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 417.10 Mn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn -153.10 Mn
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 53.61 Mn
10 Lyra Therapeutics - - - -6.16 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 -6.16 Mn
Sep 30, 2025 -7.73 Mn
Jun 30, 2025 -1.95 Mn
Mar 31, 2025 -8.84 Mn
Dec 31, 2024 16.78 Mn
Sep 30, 2024 -8.11 Mn
Jun 30, 2024 16.11 Mn
Mar 31, 2024 -5.95 Mn
Dec 31, 2023 -2.50 Mn
Sep 30, 2023 -29.51 Mn
Jun 30, 2023 32.34 Mn
Mar 31, 2023 -10.53 Mn
Dec 31, 2022 -77.03 Mn
Sep 30, 2022 -11.11 Mn
Jun 30, 2022 88.00 Mn
Mar 31, 2022 -11.99 Mn
Dec 31, 2021 -12.38 Mn
Sep 30, 2021 -10.92 Mn
Jun 30, 2021 2.94 Mn
Mar 31, 2021 -8.49 Mn
Dec 31, 2020 -6.96 Mn
Sep 30, 2020 -5.04 Mn
Jun 30, 2020 51.35 Mn
Mar 31, 2020 25.44 Mn
Dec 31, 2019 -4.20 Mn
Sep 30, 2019 -3.84 Mn
Jun 30, 2019 -2.99 Mn
Mar 31, 2019 -3.06 Mn